Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Syneos Health helps drugmakers test new medicines in clinical trials and then sells and markets those drugs once they are approved.
Syneos Health is a behind-the-scenes partner to the drug industry. When a pharmaceutical or biotech company has a promising molecule and needs to prove it actually works and is safe, Syneos runs the clinical trials — finding patients, managing sites, collecting and analyzing the data, and handling the paperwork that regulators demand. Then, once a drug is approved, Syneos helps sell it: its commercial arm fields sales reps, runs marketing campaigns, and handles market access and medical affairs for drugmakers who would rather outsource that machinery than build it themselves.
The business is essentially two engines under one roof. The clinical side is project-based contract research — customers pay for studies that can stretch over years, which makes revenue lumpy and tied to how many trials big drugmakers decide to launch. The commercial side is more recurring, closer to an outsourced salesforce and marketing shop. Syneos argues that having both lets it follow a drug from the lab all the way to the pharmacy shelf, a "clinical to commercial" pitch that few rivals offer at the same scale. Its main competitors are the big contract research organizations like IQVIA, ICON, and Charles River Laboratories, plus in-house teams at the drugmakers themselves. The company has had a rocky run as a public stock. It was formed in 2017 when INC Research merged with inVentiv Health, a deal meant to combine trial services with commercial muscle. But the shares sagged for years as trial bookings slowed and drugmakers tightened spending. In 2023, private equity firm Thomas H. Lee Partners and buyers including Elliott Investment Management took Syneos private in a deal valued at roughly $7 billion, ending its run on the public market.
That take-private matters because it tells you what the buyers saw: a steady, cash-generating services business whose public valuation had gotten cheap. Clinical trials are expensive, slow, and increasingly complicated, so drugmakers keep handing them to specialists. The risk is that this is a people business — keeping talented investigators and sales reps is hard, and a few lost big contracts can sting. But as long as new drugs keep needing testing and selling, Syneos gets paid to do the unglamorous work behind them.
Saved answer · last researched 15 Nov 2026